Cetuximab sarotalocan  (Synonyms: RM-1929; Cetuximab-IRDye-700DX)

Cetuximab sarotalocan (RM-1929) is an IRdye700DX (near-infrared photosensitizing dye) conjugate of Cetuximab (anti-EGFR monoclonal antibody). Cetuximab sarotalocan can be used for head and neck cancers research^[1][2].

Cetuximab sarotalocan sodium is formed by an antibody-photosensitive complex that combines Cetuximab, an epidermal growth factor receptor monoclonal antibody, with the dye IRdye700DX, a photosensitive substance. After administration of Cetuximab sarotalocan sodium, only tumor cells are specifically destroyed by illumination with a red light at 690 nm^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

2166339-33-7

[Cetuximab sarotalocan]

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Go Omura, et al. Transnasal photoimmunotherapy with cetuximab sarotalocan sodium: Outcomes on the local recurrence of nasopharyngeal squamous cell carcinoma. Auris Nasus Larynx. 2022 Jun 29;S0385-8146(22)00167-5.  [Content Brief]

  [2]. Isaku Okamoto, et al. Quality-of-Life Evaluation of Patients with Unresectable Locally Advanced or Locally Recurrent Head and Neck Carcinoma Treated with Head and Neck Photoimmunotherapy. Cancers (Basel). 2022 Sep 11;14(18):4413.  [Content Brief]